Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GERN NASDAQ:MACK NASDAQ:RIGL NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGERNGeron$1.28-1.5%$1.39$1.09▼$4.84$816.67M0.7310.79 million shs11.32 million shsMACKMerrimack Pharmaceuticals$15.13$14.82$11.53▼$15.89$223.77M1.45396,929 shsN/ARIGLRigel Pharmaceuticals$31.70+4.1%$20.59$9.92▼$32.40$568.70M1.21434,434 shs1.37 million shsZBIOZenas BioPharma$14.63-1.1%$12.11$5.83▼$26.25$611.97MN/A145,349 shs84,361 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGERNGeron0.00%+9.40%-3.03%0.00%-72.77%MACKMerrimack Pharmaceuticals0.00%0.00%0.00%0.00%0.00%RIGLRigel Pharmaceuticals0.00%+44.68%+67.90%+70.34%+210.48%ZBIOZenas BioPharma0.00%-5.06%+30.86%+50.21%+1,462,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGERNGeron3.1419 of 5 stars3.31.00.01.32.51.70.6MACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARIGLRigel Pharmaceuticals2.5146 of 5 stars2.20.00.00.03.71.73.1ZBIOZenas BioPharma1.7242 of 5 stars3.50.00.00.02.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGERNGeron 2.56Moderate Buy$4.19227.15% UpsideMACKMerrimack Pharmaceuticals 0.00N/AN/AN/ARIGLRigel Pharmaceuticals 2.40Hold$38.2020.50% UpsideZBIOZenas BioPharma 3.00Buy$36.67150.63% UpsideCurrent Analyst Ratings BreakdownLatest MACK, GERN, ZBIO, and RIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025RIGLRigel PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$23.00 ➝ $32.007/10/2025GERNGeronThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$1.005/16/2025ZBIOZenas BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ZBIOZenas BioPharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.00(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGERNGeron$76.99M10.61N/AN/A$0.46 per share2.78MACKMerrimack PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ARIGLRigel Pharmaceuticals$179.28M3.17$1.08 per share29.38$0.19 per share166.84ZBIOZenas BioPharma$5M122.39N/AN/A$7.48 per share1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGERNGeron-$174.57M-$0.13N/AN/AN/A-53.52%-31.37%-16.01%N/AMACKMerrimack Pharmaceuticals-$1.18M$13.871.09∞N/AN/A-1.93%-1.78%N/ARIGLRigel Pharmaceuticals$17.49M$5.415.8630.19N/A36.51%438.89%57.03%N/AZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest MACK, GERN, ZBIO, and RIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025ZBIOZenas BioPharma-$1.02N/AN/AN/A$1.25 millionN/A8/6/2025Q2 2025GERNGeron-$0.03-$0.02+$0.01-$0.02$47.30 million$49.04 million8/5/2025Q2 2025RIGLRigel Pharmaceuticals$1.97$3.28+$1.31$3.28$64.58 million$101.69 million5/15/2025Q1 2025ZBIOZenas BioPharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGERNGeronN/AN/AN/AN/AN/AMACKMerrimack PharmaceuticalsN/AN/AN/AN/AN/ARIGLRigel PharmaceuticalsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGERNGeron0.447.876.97MACKMerrimack PharmaceuticalsN/A10.7810.78RIGLRigel Pharmaceuticals0.462.022.13ZBIOZenas BioPharmaN/A6.476.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGERNGeron73.71%MACKMerrimack Pharmaceuticals63.97%RIGLRigel Pharmaceuticals66.23%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipGERNGeron7.42%MACKMerrimack Pharmaceuticals30.57%RIGLRigel Pharmaceuticals9.04%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGERNGeron229638.02 million590.68 millionOptionableMACKMerrimack Pharmaceuticals42614.79 million10.27 millionOptionableRIGLRigel Pharmaceuticals16017.94 million16.32 millionOptionableZBIOZenas BioPharmaN/A41.83 million34.93 millionN/AMACK, GERN, ZBIO, and RIGL HeadlinesRecent News About These Companies44,067 Shares in Zenas BioPharma, Inc. (NASDAQ:ZBIO) Purchased by Jefferies Financial Group Inc.August 9 at 3:59 AM | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Down 8.8% - Should You Sell?August 6, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 10.2% - What's Next?August 5, 2025 | marketbeat.com3 Highly Shorted Stocks That Could Be the Next Wall Street SensationsAugust 2, 2025 | msn.comZenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's WhyJuly 29, 2025 | marketbeat.comZenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSJuly 28, 2025 | seekingalpha.comZenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?July 26, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 11.2% - Here's WhyJuly 14, 2025 | marketbeat.comInnovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3, 2025 | tipranks.comZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...June 17, 2025 | stockhouse.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 17, 2025 | prnewswire.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 16, 2025 | accessnewswire.comAZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 16, 2025 | globenewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 16, 2025 | globenewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 16, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 16, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 16, 2025 | businesswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 16, 2025 | accessnewswire.comAZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 16, 2025 | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 DeadlineJune 16, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeMACK, GERN, ZBIO, and RIGL Company DescriptionsGeron NASDAQ:GERN$1.28 -0.02 (-1.54%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.28 0.00 (0.00%) As of 08/8/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Merrimack Pharmaceuticals NASDAQ:MACKMerrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Rigel Pharmaceuticals NASDAQ:RIGL$31.70 +1.26 (+4.14%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$31.66 -0.04 (-0.14%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.Zenas BioPharma NASDAQ:ZBIO$14.63 -0.17 (-1.15%) As of 08/8/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale